(3aR,5R,6S,6aS)-6-fluoro-2,2-dimethyl-5-((R)-oxiran-2-yl)tetrahydrofuro[2,3-d][1,3]dioxole

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3aR,5R,6S,6aS)-6-fluoro-2,2-dimethyl-5-((R)-oxiran-2-yl)tetrahydrofuro[2,3-d][1,3]dioxole
• 英文别名: (3aR,5R,6S,6aS)-6-fluoro-2,2-dimethyl-5-[(2R)-oxiran-2-yl]-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole
• 化学式: C₉H₁₃FO₄
• 分子量: 204.198
• InChiKey: GQXFOIFUXVZMOC-OZRXBMAMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3aR,5R,6S,6aS)-6-fluoro-2,2-dimethyl-5-((R)-oxiran-2-yl)tetrahydrofuro[2,3-d][1,3]dioxole 在 potassium acetate 、 硫脲 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 48.0h， 生成 3-deoxy-5,6-di-O,S-acetyl-3-fluoro-1,2-O-isopropylidene-5-thio-α-D-gluco-pentofuranose
  参考文献：
  名称：

  An alternative synthesis of antineoplastic 4′-thiocytidine analogue 4′-thioFAC

  摘要：

  We have developed an alternative method for the synthesis of 2'-modified 4'-thionucleosides. The fusion of 3,5-di-O-benzoyl-1-bromo-2-deoxy-2-fluoro-4-thio-alpha-D-arabinofuranose, prepared from 1,2:5,6-diisopropylidene-alpha-D-allofuranose, with persilylated N-4-acetylcytosine predominantly gave a beta-anomer of protected 4'-thionucleoside, which was then deprotected to give 4'-thioFAC. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)00048-9
• 作为产物：
  描述：

  3-deoxy-1,2;5,6-di-O-isopropylidene-3-fluoro-α-D-glucofuranose 在 吡啶 、 双(三甲基硅烷基)氨基钾 、 溶剂黄146 作用下， 以 水 、 Petroleum ether 为溶剂， 反应 37.0h， 生成 (3aR,5R,6S,6aS)-6-fluoro-2,2-dimethyl-5-((R)-oxiran-2-yl)tetrahydrofuro[2,3-d][1,3]dioxole
  参考文献：
  名称：

  TLR7 AGONISTS

  摘要：

  本发明涉及根据式I的TLR7激动剂及其在治疗癌症和传染病等疾病中的应用。

  公开号：

  US20210155652A1

文献信息

• TLR7 AGONISTS
  申请人：Primmune Therapeutics, Inc.

  公开号：US20210155652A1

  公开（公告）日：2021-05-27

  The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

  本发明涉及根据式I的TLR7激动剂及其在治疗癌症和传染病等疾病中的应用。
• [EN] TLR7 AGONISTS<br/>[FR] AGONISTES DE TLR7
  申请人：PRIMMUNE THERAPEUTICS INC

  公开号：WO2021108649A1

  公开（公告）日：2021-06-03

  The present invention relates to TLR7 agonists according to Formula (I) and their use in the treatment of diseases such as cancer and infectious disease.
• An alternative synthesis of antineoplastic 4′-thiocytidine analogue 4′-thioFAC
  作者：Yuichi Yoshimura、Mikari Endo、Shinji Sakata

  DOI：10.1016/s0040-4039(99)00048-9

  日期：1999.3

  We have developed an alternative method for the synthesis of 2'-modified 4'-thionucleosides. The fusion of 3,5-di-O-benzoyl-1-bromo-2-deoxy-2-fluoro-4-thio-alpha-D-arabinofuranose, prepared from 1,2:5,6-diisopropylidene-alpha-D-allofuranose, with persilylated N-4-acetylcytosine predominantly gave a beta-anomer of protected 4'-thionucleoside, which was then deprotected to give 4'-thioFAC. (C) 1999 Elsevier Science Ltd. All rights reserved.